Capital raising to take Pacifico through to 2020 PFS

Published 02-SEP-2019 11:07 A.M.


2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.

Click Here to View Latest Articles

Shares in Pacifico Minerals Ltd (ASX: PMY) surged more than 10% on Monday morning after the company announced that it had raised $4.6 million, funding which will significantly progress the advancement of the company’s Sorby Hills Lead-Silver-Zinc Joint Venture Project in Western Australia.

Pacifico shares have now increased 100% in the last two months, and there could be more to come.

The company owns a 75% interest in the Joint Venture with the remaining 25% interest held by Henan Yuguang Gold & Lead Co. Ltd.

Phase II infill and expansion drilling results are imminent, and these have the potential to provide further share price momentum.

On the back of a highly successful Phase II drilling program, Pacifico will use additional available funding to commence a Phase III drilling program within the next two months.

PFS and DFS both on track for 2020

The company is now fully funded to deliver an optimised prefeasibility study by January 2020, a watershed development as the company progresses towards a decision to mine.

Pacifico will also be advancing its definitive feasibility study work program, highlighting the extensive news flow that is in the pipeline.

Discussing the significance of the capital raising, managing director, Simon Noon said, “The response to the capital raising from both new professional investors and our major shareholders has been extremely encouraging and I believe this is testament to the strong results the Sorby Hills project is consistently delivering.

“This funding will enable the company to complete an additional infill and expansion drilling program this year, just prior to the release of the optimised PFS ahead of the Definitive Feasibility Study (DFS) to be delivered next year.”

As indicated in the following six-month chart, commodity prices have been working in Pacifico’s favour, with the two key metals, silver (black line) and lead (green line), both performing well in the last six months.

While stocks leveraged to silver have been running hard, Pacifico’s exposure to lead is worth noting given that it is bucking the broader negative trends across some other base metals.

General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.


Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free